Cart
sales@molnova.com
FEN1-IN-3
CAS No. 2109805-87-8
FEN1-IN-3( —— )
Catalog No. M37614 CAS No. 2109805-87-8
FEN1-IN-3 is a human flap endonuclease-1 ( hFEN1 ) inhibitor that stabilizes hFEN1 with an EC 50 of 6.8 μM .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 33 | In Stock |
|
| 5MG | 30 | In Stock |
|
| 10MG | 51 | In Stock |
|
| 25MG | 91 | In Stock |
|
| 50MG | 145 | In Stock |
|
| 100MG | 243 | In Stock |
|
| 200MG | 338 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFEN1-IN-3
-
NoteResearch use only, not for human use.
-
Brief DescriptionFEN1-IN-3 is a human flap endonuclease-1 ( hFEN1 ) inhibitor that stabilizes hFEN1 with an EC 50 of 6.8 μM .
-
DescriptionFEN1-IN-3 (Compound 4) is a human flap endonuclease-1 (hFEN1) inhibitor. FEN1-IN-3 stabilizes hFEN1 with an EC50 of 6.8 μM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2109805-87-8
-
Formula Weight284.27
-
Molecular FormulaC15H12N2O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (879.45 mM; Ultrasonic )
-
SMILESCOc1ccc(cc1)-n1c2ccccc2c(=O)n(O)c1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jack C Exell, et al. Cellularly Active N-hydroxyurea FEN1 Inhibitors Block Substrate Entry to the Active Site. Nat Chem Biol. 2016 Oct;12(10):815-21.?
molnova catalog
related products
-
TAK-448 acetate
TAK-448 is a KISS1R protein agonist as a oligopeptide analog of kisspeptin,TAK-448 acetate (MVT-602 acetate) is a potent and full KISS1R agonist with an IC50 of 460 pM and an EC50 of 632 pM.
-
Neurokinin A(4-10) T...
Neurokinin A (4-10) TFA is a tachykinin NK2 receptor agonist.
-
Dimethylaminomicheli...
Dimethylaminomicheliolide HCl has potential anti-inflammatory and anti-tumor activity and inhibits the proliferation of glioblastoma cells by targeting pyruvate kinase 2 (PKM2) and reconnecting aerobic cell populations.
